PlainPharmaWatch

CMS Open Payments · Program Year 2024

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. reported $18,731,989.24 in payments to 100,133 physicians and teaching hospitals across 101,993 transactions.

See the rankings → How this is sourced
$18.7M
Total payments
101,993
Transactions
100,133
Recipients
−$1.5M
General Payments vs PY2023

Neurocrine Biosciences, Inc. reported $18,731,989.24 in payments to 100,133 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #97 of 1,925 reporting manufacturers (0.1% of all US industry payments), averaging $187.07 per recipient across 8 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Neurocrine Biosciences, Inc. pairs top-5% payment volume with an unusually diversified payment pattern across a wide recipient base.

#97
of 1,925 companies
0.1%
of all US industry payments
0.0%
paid to its single top recipient
8
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Neurocrine Biosciences, Inc.'s CMS-reported General Payments decreased by $1.5M (−9.4%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: NEUROCRINE BIOSCIENCES, INC.PY2023: NEUROCRINE BIOSCIENCES, INC.PY2024: Neurocrine Biosciences, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$15.7MPY2024$14.2M
PY2023
$15,684,940.88
PY2024
$14,217,673.38

How Neurocrine Biosciences, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Neurocrine Biosciences, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$18,731,989 Top 5% higher than 95% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). This entry sits in this band. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Neurocrine Biosciences, Inc.

Rank #97 of 1,925 companies in CMS Open Payments for 2024 belongs to Neurocrine Biosciences, Inc., which reported $18,731,989.24 across 101,993 transactions to 100,133 recipients - representing 0.1% of all industry payments reported nationwide for the year. Averages work out to $183.66 per transaction and $187.07 per recipient.

"Compensation for Services Other Than Consulting" leads the 8-category general-payment breakdown below at $7.2M (38.5% of the company's reported total, 2,307 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 8 types of general payments, Neurocrine Biosciences, Inc.'s largest category was "Compensation for Services Other Than Consulting" at $7.2M - 38.5% of the company's reported total.

How Neurocrine Biosciences, Inc. divides its payments

General-payment categories, ordered by reported total

1. Compensation for Services…$7.2M2. Consulting Fee$2.9M3. Food and Beverage$2.6M4. Travel and Lodging$1.2M5. Space Rental or Facility …$130.2K6. Royalty or License$107.5K7. Grant$100.0K8. Education$47.74
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $7.2M 2,307
Consulting Fee $2.9M 511
Food and Beverage $2.6M 92,556
Travel and Lodging $1.2M 4,724
Space Rental or Facility Fees $130.2K 18
Royalty or License $107.5K 3
Grant $100.0K 1
Education $47.74 13

Recipient Concentration in General Payments

The five largest recipient relationships account for $932,996.02 (6.6%) of $14,217,673.38 in this company's General Payments records across 25,729 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Neurocrine Biosciences, Inc.

The five named recipients with the highest reported General Payments from this company

Stephen Sherwin$429.0KAmy M Lacouture$130.5KPrakash S Masand$130.0KRakesh Amin$122.5KDenise de Angelis$120.9K
  1. 1

    Stephen Sherwin

    $429,043.10 across 48 reported transactions

  2. 2

    Amy M Lacouture

    $130,539.87 across 237 reported transactions

  3. 3

    Prakash S Masand

    $130,020.46 across 122 reported transactions

  4. 4

    Rakesh Amin

    $122,470.02 across 124 reported transactions

  5. 5

    Denise de Angelis

    $120,922.57 across 122 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $183.66. Average per recipient: $187.07.

Total Amount

$18,731,989.24

Avg per Transaction

$183.66

Avg per Recipient

$187.07

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Neurocrine Biosciences, Inc. Share

0.1%

#97 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Neurocrine Biosciences, Inc.

AngioDynamics, Inc.

$18.8M 12,056 recipients

UCB, Inc.

$18.5M 154,022 recipients

Sun Pharmaceutical Industries Inc.

$18.3M 77,951 recipients

Spinecraft, LLC

$18.2M 27 recipients

Dexcom, Inc.

$19.3M 55,653 recipients

CSL Plasma Inc.

$17.9M 12,905 recipients

Frequently Asked Questions

How much did Neurocrine Biosciences, Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $18,731,989.24 from Neurocrine Biosciences, Inc. to physicians and hospitals across 101,993 transactions - 0.1% of all industry payments reported that year.
How many physicians received payments from Neurocrine Biosciences, Inc.? ▾
Averaging $187.07 per recipient, Neurocrine Biosciences, Inc.'s 2024 payments reached 100,133 physicians and teaching hospitals.
What types of payments did Neurocrine Biosciences, Inc. make? ▾
Neurocrine Biosciences, Inc. made 8 different types of general payments (consulting, meals, travel, and similar categories). The largest general-payment category was "Compensation for Services Other Than Consulting" at $7.2M, representing 38.5% of the company's reported total.
How does Neurocrine Biosciences, Inc. rank among pharmaceutical companies? ▾
Neurocrine Biosciences, Inc. ranks #97 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from Neurocrine Biosciences, Inc.? ▾
Neurocrine Biosciences, Inc.'s 101,993 transactions to 100,133 recipients in 2024 averaged $183.66 per transaction.
Where does the payment data for Neurocrine Biosciences, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Neurocrine Biosciences, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.